{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:31:44Z","timestamp":1759336304971},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12325-018-0696-y","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T20:17:25Z","timestamp":1523045845000},"page":"457-466","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Decline in Buprenorphine\/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail"],"prefix":"10.1007","volume":"35","author":[{"given":"Richard","family":"Soper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sireesh","family":"Appajosyula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Deximo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"696_CR1","first-page":"002025","volume":"3","author":"L Gowing","year":"2009","unstructured":"Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009;3:002025.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"696_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/ern.09.26","volume":"9","author":"W Ling","year":"2009","unstructured":"Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9(5):609\u201316.","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"696_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","volume":"104","author":"J Bell","year":"2009","unstructured":"Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193\u2013200.","journal-title":"Addiction"},{"issue":"1\u20133","key":"696_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2008.07.013","volume":"99","author":"ES Jones","year":"2009","unstructured":"Jones ES, Moore BA, Sindelar JL, O\u2019Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99(1\u20133):132\u201340.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"696_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949\u201358.","journal-title":"N Engl J Med"},{"key":"696_CR6","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6105.1000146","author":"K Blum","year":"2013","unstructured":"Blum K, Oscar-Berman M, Femino J, et al. Withdrawal from buprenorphine\/naloxone and maintenance with a natural dopaminergic agonist: a cautionary note. J Addict Res Ther. 2013. \n                    https:\/\/doi.org\/10.4172\/2155-6105.1000146\n                    \n                  .","journal-title":"J Addict Res Ther"},{"issue":"5","key":"696_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1521-0391.2014.12133.x","volume":"23","author":"M Makhinson","year":"2014","unstructured":"Makhinson M, Gomez-Makhinson J. A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. Am J Addict. 2014;23(5):475\u20137.","journal-title":"Am J Addict"},{"issue":"1","key":"696_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","volume":"47","author":"EJ Lavonas","year":"2014","unstructured":"Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47(1):27\u201334.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"696_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s002130050804","volume":"141","author":"J Mendelson","year":"1999","unstructured":"Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology. 1999;141(1):37\u201346.","journal-title":"Psychopharmacology"},{"issue":"3","key":"696_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130000637","volume":"154","author":"KB Stoller","year":"2001","unstructured":"Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine\/naloxone in opioid-dependent humans. Psychopharmacology. 2001;154(3):230\u201342.","journal-title":"Psychopharmacology"},{"issue":"4","key":"696_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/adb.12163","volume":"20","author":"JD Jones","year":"2015","unstructured":"Jones JD, Sullivan MA, Vosburg SK, et al. Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users. Addict Biol. 2015;20(4):784\u201398.","journal-title":"Addict Biol"},{"key":"696_CR12","unstructured":"ZUBSOLV\u00ae Full Prescribing Information (2016). Orexo US, Inc., Morristown."},{"key":"696_CR13","unstructured":"SUBOXONE\u00ae Full Prescribing Information (2016). Indivior, Inc., Richmond."},{"key":"696_CR14","unstructured":"BUNAVAIL\u00ae Full Prescribing Information (2016). BioDelivery Sciences International, Inc., Raleigh."},{"issue":"142","key":"696_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","volume":"1","author":"TJ Cicero","year":"2014","unstructured":"Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008\u20132013. Drug Alcohol Depend. 2014;1(142):98\u2013104.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"696_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","volume":"122","author":"R Daniulaityte","year":"2012","unstructured":"Daniulaityte R, Falck R, Carlson RG. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2012;122(3):201\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"696_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1874473711104010028","volume":"4","author":"MA Yokell","year":"2011","unstructured":"Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28\u201341.","journal-title":"Curr Drug Abuse Rev"},{"issue":"3","key":"696_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","volume":"5","author":"AR Bazazi","year":"2011","unstructured":"Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine\/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5(3):175\u201380.","journal-title":"J Addict Med"},{"key":"696_CR19","unstructured":"StreetRx.com. Street prices for buprenorphine\/naloxone. Accessed May 26, 2017."},{"issue":"3","key":"696_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pme.12295","volume":"15","author":"TA Cassidy","year":"2014","unstructured":"Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15(3):440\u201351.","journal-title":"Pain Med"},{"issue":"165","key":"696_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drugalcdep.2016.06.009","volume":"1","author":"HD Chilcoat","year":"2016","unstructured":"Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug Alcohol Depend. 2016;1(165):221\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"168","key":"696_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","volume":"1","author":"SG Severtson","year":"2016","unstructured":"Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;1(168):219\u201329.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"696_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.clinthera.2015.02.027","volume":"37","author":"JG Sullivan","year":"2015","unstructured":"Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine\u2013naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. Clin Ther. 2015;37(5):1064\u201375.","journal-title":"Clin Ther"},{"key":"696_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMsa1406143","volume":"372","author":"RC Dart","year":"2015","unstructured":"Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. NEJM. 2015;372:241\u20138.","journal-title":"NEJM"},{"issue":"12","key":"696_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/pds.1659","volume":"17","author":"SF Butler","year":"2008","unstructured":"Butler SF, Budman SH, Licari A, et al. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17(12):1142\u201354.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"696_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","volume":"8","author":"TJ Cicero","year":"2007","unstructured":"Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Mu\u00f1oz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). Pain Med. 2007;8(2):157\u201370.","journal-title":"Pain Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0696-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T00:40:06Z","timestamp":1554597606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0696-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0696-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"16 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}